CY1108087T1 - ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa - Google Patents

ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa

Info

Publication number
CY1108087T1
CY1108087T1 CY20081100491T CY081100491T CY1108087T1 CY 1108087 T1 CY1108087 T1 CY 1108087T1 CY 20081100491 T CY20081100491 T CY 20081100491T CY 081100491 T CY081100491 T CY 081100491T CY 1108087 T1 CY1108087 T1 CY 1108087T1
Authority
CY
Cyprus
Prior art keywords
tafia
imidazoli
suspensions
products
compounds
Prior art date
Application number
CY20081100491T
Other languages
Greek (el)
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Grueneberg
Hauke Szillat
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108087(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of CY1108087T1 publication Critical patent/CY1108087T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20081100491T 2004-04-22 2008-05-12 ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa CY1108087T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
EP05731221A EP1740569B1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
CY1108087T1 true CY1108087T1 (el) 2014-02-12

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100491T CY1108087T1 (el) 2004-04-22 2008-05-12 ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa

Country Status (34)

Country Link
EP (2) EP1864979B1 (cg-RX-API-DMAC10.html)
JP (1) JP4939401B2 (cg-RX-API-DMAC10.html)
KR (1) KR101162047B1 (cg-RX-API-DMAC10.html)
CN (1) CN100572376C (cg-RX-API-DMAC10.html)
AR (1) AR053302A1 (cg-RX-API-DMAC10.html)
AT (2) ATE523505T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005238144B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0510159A (cg-RX-API-DMAC10.html)
CA (1) CA2563401C (cg-RX-API-DMAC10.html)
CR (1) CR8650A (cg-RX-API-DMAC10.html)
CY (1) CY1108087T1 (cg-RX-API-DMAC10.html)
DE (2) DE102004020186A1 (cg-RX-API-DMAC10.html)
DK (1) DK1740569T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP066941A (cg-RX-API-DMAC10.html)
ES (1) ES2299026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20080099T3 (cg-RX-API-DMAC10.html)
IL (1) IL178672A (cg-RX-API-DMAC10.html)
MA (1) MA28543B1 (cg-RX-API-DMAC10.html)
MY (1) MY140903A (cg-RX-API-DMAC10.html)
NI (1) NI200600217A (cg-RX-API-DMAC10.html)
NO (1) NO20065320L (cg-RX-API-DMAC10.html)
NZ (1) NZ550757A (cg-RX-API-DMAC10.html)
PE (1) PE20060172A1 (cg-RX-API-DMAC10.html)
PL (1) PL1740569T3 (cg-RX-API-DMAC10.html)
PT (1) PT1740569E (cg-RX-API-DMAC10.html)
RS (1) RS50553B (cg-RX-API-DMAC10.html)
RU (1) RU2375356C2 (cg-RX-API-DMAC10.html)
SI (1) SI1740569T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06341A1 (cg-RX-API-DMAC10.html)
TW (1) TWI359016B (cg-RX-API-DMAC10.html)
UA (1) UA87306C2 (cg-RX-API-DMAC10.html)
UY (1) UY28868A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005105781A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607668B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
MX2010012793A (es) * 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
US8865906B2 (en) * 2009-05-15 2014-10-21 Sanofi Process for the preparation of a compound useful as an inhibitor of TAFIa
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
WO2012062730A1 (en) 2010-11-11 2012-05-18 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782576B1 (en) * 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012338A3 (cs) * 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
UY28868A1 (es) 2005-11-30
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
ZA200607668B (en) 2008-03-26
KR20070007346A (ko) 2007-01-15
SI1740569T1 (sl) 2008-06-30
PT1740569E (pt) 2008-03-31
ES2299026T3 (es) 2008-05-16
CR8650A (es) 2007-12-04
RS50553B (sr) 2010-05-07
HK1101823A1 (zh) 2007-10-26
NZ550757A (en) 2010-06-25
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
DE102004020186A1 (de) 2005-11-17
HRP20080099T3 (en) 2008-03-31
EP1740569A1 (de) 2007-01-10
JP2007533672A (ja) 2007-11-22
EP1864979A1 (de) 2007-12-12
IL178672A (en) 2011-08-31
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
TNSN06341A1 (en) 2008-02-22
KR101162047B1 (ko) 2012-07-04
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
PE20060172A1 (es) 2006-03-31
MA28543B1 (fr) 2007-04-03
RU2375356C2 (ru) 2009-12-10
AU2005238144B2 (en) 2010-08-26
EP1740569B1 (de) 2008-02-20
NI200600217A (es) 2008-06-17
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
AR053302A1 (es) 2007-05-02
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
WO2005105781A1 (de) 2005-11-10
EP1864979B1 (de) 2011-09-07
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
ATE386737T1 (de) 2008-03-15
DK1740569T3 (da) 2008-06-02
CA2563401C (en) 2012-08-07
DE502005002927D1 (de) 2008-04-03
MY140903A (en) 2010-01-29
ATE523505T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
CY1117379T1 (el) Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
CY1110108T1 (el) Παραγωγα ισοκινολινης ως αναστολεις της rho-κινασης
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
EA202091530A1 (ru) Диазаиндольные соединения
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
CY1118476T1 (el) Νεοι αναστολεις του μονοπατιου stat3 και αναστολεις καρκινικων βλαστοκυτταρων
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
ATE510827T1 (de) Inhibitoren von proteinkinasen
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
NO20082266L (no) Nye 1-azabicykloalkylderivater for behandling av psykotiske og neurodegenerative forstyrrelser
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
EA201200555A1 (ru) Производные карболина, полезные в ингибировании ангиогенеза
CR9378A (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
CY1115604T1 (el) Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
NO20085135L (no) Selektive inhibitorer av ROCK-proteinkinase og anvendelse derav
EA201170344A1 (ru) Азаиндольные ингибиторы iap
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer
CY1123438T1 (el) Διαδικασια για παραγωγη και καθαρισμοανασυνδυασμενης λυσοσωμικης αλφα-μαννοσιδασης